ReviewMolecular biotechnology2026
Quantifying HER-2 for Precision Oncology: The Role of Optical Biosensors.
Review in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to measure the Human Epidermal Growth Factor Receptor 2 (HER-2), a biomarker associated with aggressive breast cancer and other malignancies, is vital to both providing an accurate diagnosis and tailoring individualized therapeutic management of patients. Although traditional approaches to diagnose HER-2 through laboratory testing using immunohistochemical techniques are established methods, they may be slow, semi-quantitative, and dependent on centralized laboratory facilities. This review first provides a concise overview of the biomarker HER-2 and its role in cancer, then proceeds to review recent advances in optical biosensing platforms designed for the sensitive and specific detection of HER-2. We describe how various optical transducers, including fluorescence, surface plasmon resonance (SPR), and colorimetric assays, are being used for quantification of HER-2 in clinical and experimental settings. We also highlight emerging point-of-care (POC) devices that utilize optical technologies for rapid, decentralized HER-2 measurement. In conclusion, this review discusses current challenges associated with the clinical translation of optical biosensors, including standardization, large-scale validation, and regulatory implementation, while also highlighting future directions involving nanotechnology integration, liquid biopsy strategies, and AI-assisted diagnostic systems for precision oncology.
Indexed as
Identifiers
42730986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.